95% CI, 2.52 to 7.86) [73]
5 Conclusion DM as a major challenge in global public health, is showing a serious trend of increasing prevalence year by year
(2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
These mechanisms address different root causes of weight gainmetformin tackles insulin resistance, and semaglutide reduces hunger and caloric intake
Social Pressure and Perception The pressure to lose weight is nearly universal, but not evenly distributed
GLP1R agonists increase heart rate and might not be beneficial in individuals with severe left ventricular dysfunction, reduced ejection fraction and/or a history of repeated hospitalization for heart failure